
**SOME IMMUNOLOGICAL ABNORMALITIES
IN CHRONIC HEPATITIS 'C' AMONG
EGYPTIAN PATIENTS**

Thesis

SUBMITTED FOR PARTIAL FULFILLMENT OF M.D. DEGREE
IN CLINICAL PATHOLOGY

By

6/6-79
M.A **Mona Mahmoud El-Sayed Hassouna**
(M.B. B.Ch., M.Sc. Clinical Pathology)

Supervised By

63119
Dr **Prof. Dr. Aida Abd El-Azeem Abd El-Salam**

Professor of Clinical Pathology,
Faculty of Medicine, Ain Shams University

[Signature] **Prof. Dr. Ahmed Abbass Raouf**

Professor of Biochemistry and Dean of Liver Institute
Menoufiya University

6/5/98 **Prof. Dr. Saleh Mahmoud Saleh**

Professor and Head of Internal Medicine Dept.
Liver Institute, Menoufiya University

6/5/98 **Dr. Hala Ahmed Talkhan**

Assistant Professor of Clinical Pathology,
Faculty of Medicine, Ain Shams University

[Stamp]
FACULTY OF MEDICINE
AIN SHAMS UNIVERSITY

1998







To ..

- *My mother.*
- *My husband Ismail*
- *My lovely daughters
Yumna and Sara*

ACKNOWLEDGEMENT

First of all Thanks to GOD

There are so many people I feel indebted to ... so many people I would like to thank, ... all those people who gave me a hand either practically or morally throughout the performance of this study.

I would like to express my deepest gratitude and great thanks to **rof. Dr. Aida Abd El-Azim Abd El-Salam**, Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her motherly advice, continuous encouragement and meticulous supervision.

I would like also to express my deepest thanks and appreciation to **rof. Dr. Ahmed Abass Raouf**, Professor of Biochemistry and Dean of Liver Institute, Menoufiya University, for his continuous encouragement and unlimited support during carrying out this thesis.

I am very grateful to **Prof. Dr. Saleh Mahmoud Saleh**, Professor of Medicine and Head of Medicine Department, Liver Institute, Menoufiya University, for his help and continuous advice.

My deepest thanks and profound gratitude to **Dr. Hala Talkhan**, Assistant Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her continuous unlimited help and very useful advices throughout the work.

I am very grateful to **Dr. Ahmed El-Shaarawy**, Lecturer of Clinical Pathology, Liver Institute, Menoufiya University, for his help in IFT.

Many thanks to **Dr. Hatem El-Sebaay**, Lecturer of Biochemistry, Faculty of Medicine, Menoufiya University for his help in the PCR procedure.

I would like also to thank **Dr. Khaled Gamil**, Assistant Lecturer of Medicine, Liver Institute, Menoufiya University and **Dr. Nashwa Hible**, Resident of Medicine, Liver Institute, Menoufiya University, for their help in selection of C virus chronic hepatitis patients.

My deepest thanks and full appreciation to my mother who gave me and still giving me a lot.

CONTENTS

| | |
|---|-----|
| Introduction | 1 |
| Aim of the work | 2 |
| Review of Literature | 3 |
| • Historical background | 3 |
| • Molecular virology of hepatitis C virus | 4 |
| • Epidemiology of HCV | 10 |
| • Modes of transmission of HCV | 14 |
| • HCV genotypes | 18 |
| • Diagnosis of HCV | 21 |
| • Pathogenesis of hepatic damage in HCV infection | 35 |
| • Clinical course of HCV infection | 37 |
| • HCV and HCC | 42 |
| • HCV and schistosomiasis | 43 |
| • Some immunological abnormalities in chronic HCV | 45 |
| Subjects and Methods | 62 |
| Results | 73 |
| Discussion | 104 |
| Summary and conclusion | 116 |
| References | 119 |

LIST OF FIGURES

| | |
|---|----|
| Fig. (1): Structure and processing of the HCV polyprotein by cellular signal peptidases and virally encoded proteases | 5 |
| Fig. (2): Phylogenetic analysis of nucleotide sequence in most of HCV NS-5 region | 19 |
| Fig. (3): Recombinant HCV antigens and three generations of EIA for detection of anti-HCV | 22 |
| Fig. (4): Schematic outline of PCR | 26 |
| Fig. (5): Schematic outline of bDNA assay | 29 |
| Fig. (6): Schematic outline of AG-LCR | 31 |
| Fig. (7): Schematic outline of NASBA | 33 |
| Fig. (8): Natural history of hepatitis C viral infection | 40 |
| Fig. (9) : Agarose gel showing bands of HCV RNA by PCR | 68 |
| Fig. (10) : Positive ASMA by indirect IFT | 7 |
| Fig. (11) : Positive ANA (speckled) by indirect IFT | 7 |
| Fig. (12) : Positive ATA (antimicrosomal) by indirect IFT | 72 |
| Fig. (13): Mean values of liver enzymes in both patients and control groups | 92 |
| Fig. (14) : Mean values of CICs in both patients and control groups | 93 |
| Fig. (15) : Results of ASMA in patients with chronic HCV and chronic HBV infection | 94 |
| Fig. (16) : Results of ANA in patients with chronic HCV and chronic HBV infection | 95 |

| | |
|---|-----|
| Fig. (17) : Results of ATA in patients with chronic HCV and chronic HBV infection | 96 |
| Fig. (18) : Results of AMA in patients with chronic HCV and chronic HBV infection | 97 |
| Fig. (19) : Results of LKM in patients with chronic HCV and chronic HBV infection | 98 |
| Fig. (20) : Results of RF in patients with chronic HCV and chronic HBV infection | 99 |
| Fig. (21) : Results of IHA for Bilharziasis in both patients and control groups | 100 |
| Fig. (22) : Results of positive autoantibodies in chronic HCV patients with and without liver cirrhosis | 101 |
| Fig. (23) : Results of positive autoantibodies in both female and male patients with chronic HCV infection | 102 |
| Fig. (24) : Association between presence or absence of schistosomiasis and incidence of positive autoantibodies | 103 |

LIST OF TABLES

| | |
|---|----|
| Table (1): Comparison of antibody detection and nucleic acid amplification for HCV | 25 |
| Table (2): Descriptive statistics of different studied parameters in chronic HCV infection (group I) (n= 42) | 79 |
| Table (3): Descriptive statistics of different studied parameters in chronic HBV infection (group II) (n= 20) | 80 |
| Table (4): Descriptive statistics of different studied parameters in control (group III) (n= 30) | 81 |
| Table (5): Frequency (%) of qualitative data studied in chronic HCV (group I) (n= 42) | 82 |
| Table (6): Frequency of qualitative data studied in chronic HBV group (group II) (n= 20) | 83 |
| Table (8): Statistical comparison between chronic HCV (group I) and control (group III) groups regarding different parameters studied | 84 |
| Table (9): Statistical comparison between chronic HBV (group II) and control (group III) groups regarding different parameters studied | 85 |
| Table (10): Statistical comparison between chronic HCV (group I) and chronic HBV (group II) groups of patients regarding different parameters studied | 86 |
| Table (11): Statistical comparison between chronic HCV (group I) and chronic HBV (group II) groups of patients regarding autoantibodies | 87 |

| | |
|---|----|
| Table (12): Statistical comparison between chronic HCV (group I) and control (group III) groups regarding autoantibodies and CICs | 88 |
| Table (13): Statistical comparison between chronic HBV (group II) and control (group III) groups regarding autoantibodies | 88 |
| Table (14): Statistical comparison between patients with chronic HCV with and without liver cirrhosis regarding autoantibodies | 89 |
| Table (15): Statistical comparison between female and male sex in patients with chronic HCV (group I) regarding autoantibodies | 90 |
| Table (16): Statistical comparison between the presence or absence of schistosomal antibodies and the incidence of autoantibodies in patients of group (I) | 91 |

LIST OF ABBREVIATIONS

| | |
|--------|--------------------------------------|
| Ag-LCR | Asymmetric gap-ligase chain reaction |
| ALT | Alanine transferase |
| AMA | Antimitochondrial antibody |
| ANA | Antinuclear antibody |
| ASMA | Antismooth muscle antibody |
| AST | Aspartate transferase |
| bdDNA | branched DNA |
| CAH | Chronic active hepatitis |
| CICS | Circulating immune complexes |
| D.B. | Direct bilirubin |
| G-LCR | Gap-ligase chain reaction |
| HBcAb | Hepatitis B core antibody |
| HBsAg | Hepatitis B surface antigen |
| HBV | Hepatitis B virus |
| HCV | Hepatitis C virus |
| HIV | Human immunodeficiency virus |
| IFT | Immune fluorescent technique |
| IHA | Indirect haemagglutination |
| LCR | Ligase chain reaction |
| LKM | Liver kidney microsome |
| NANB | non-A, non-B |
| NASBA | Nucleic acid sequence based assay |
| ORF | Open reading frame |
| PBC | Primary biliary cirrhosis |
| PCR | Polymerase chain reaction |
| R.F. | Rheumatoid factor |
| RIBA | Recombinant immunoblot assay |
| RT | Reverse transcription |
| Th1 | T-helper-1 |
| Th2 | T-helper-2 |
| UTR | Untranslated region |